Piper Jaffray analyst David Amsellem calls Horizon Pharma (HZNP) his top "growth oriented/GARP idea" for 2019. The company offers high asset quality, visibility into significant longer-term EBITDA growth, and manageable debt levels that enable significant business development flexibility, Amsellem tells investors in a research note. He believes the Specialty Pharmaceuticals group is well positioned to perform more in-line with the broader therapeutics and overall healthcare spaces in 2019, or "certainly better than what we have seen in recent years." The analyst names Bausch Health (BHC), a stock he upgraded this morning to Overweight, his top "de-leveraging/defensive pick" for 2019. Further, Amsellem's top "development-stage picks" for 2019 are Cara Therapeutics (CARA) and Revance Therapeutics (RVNC).